These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37362561)

  • 1. Corrigendum for efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).
    Pulm Circ; 2023 Apr; 13(2):e12250. PubMed ID: 37362561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
    Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
    Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
    Liu YY; Qu YY; Wang S; Luo CJ; Qiu HL; Li HT; Yuan P; Wang L; Li JL; Jiang R; Zhang R
    Front Pharmacol; 2023; 14():1155631. PubMed ID: 36891269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
    Rubin LJ; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA
    Eur Respir J; 2015 May; 45(5):1303-13. PubMed ID: 25614164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).
    Ghofrani HA; Grünig E; Jansa P; Langleben D; Rosenkranz S; Preston IR; Rahaghi F; Sood N; Busse D; Meier C; Humbert M
    Pulm Circ; 2020; 10(3):2045894020942121. PubMed ID: 32728421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
    Humbert M; Coghlan JG; Ghofrani HA; Grimminger F; He JG; Riemekasten G; Vizza CD; Boeckenhoff A; Meier C; de Oliveira Pena J; Denton CP
    Ann Rheum Dis; 2017 Feb; 76(2):422-426. PubMed ID: 27457511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum for
    Pulm Circ; 2021; 11(2):20458940211007752. PubMed ID: 33854769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison.
    Wang C; Jing ZC; Huang YG; Zhou DX; Liu ZH; Meier C; Nikkho S; Curram J; Zhang P; He JG
    Heart Asia; 2016; 8(1):74-82. PubMed ID: 27326239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study.
    Benza RL; Boucly A; Farber HW; Frost AE; Ghofrani HA; Hoeper MM; Lambelet M; Rahner C; Bansilal S; Nikkho S; Meier C; Sitbon O
    J Heart Lung Transplant; 2022 Mar; 41(3):411-420. PubMed ID: 34848133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riociguat for the treatment of pulmonary arterial hypertension.
    Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
    N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension.
    Willmann S; Keller AK; Meyer M; van der Mey D; Wirsching G; Zhang Y; Drenth HJ; Keunecke A; Vendel E; Saleh S
    Pediatr Pulmonol; 2023 Mar; 58(3):908-917. PubMed ID: 36507572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Benza RL; Ghofrani HA; Grünig E; Hoeper MM; Jansa P; Jing ZC; Kim NH; Langleben D; Simonneau G; Wang C; Busse D; Meier C; Ghio S
    J Heart Lung Transplant; 2021 Oct; 40(10):1172-1180. PubMed ID: 34353714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension.
    Galiè N; Müller K; Scalise AV; Grünig E
    Eur Respir J; 2015 May; 45(5):1314-22. PubMed ID: 25657022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies.
    Thenappan T; Al-Naamani N; Ghio S; Ghofrani HA; Hassoun PM; Pritzker M; Torbicki A; Nikkho S; Busse D; Preston IR
    Pulm Circ; 2020; 10(4):2045894020963836. PubMed ID: 33282192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
    Saleh S; Becker C; Frey R; Mück W
    Pulm Circ; 2016 Mar; 6(Suppl 1):S86-96. PubMed ID: 27162632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Hill NS; Rahaghi FF; Sood N; Frey R; Ghofrani HA
    Respir Med; 2017 Aug; 129():124-129. PubMed ID: 28732819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.
    Morales-Cano D; Izquierdo-García JL; Barreira B; Esquivel-Ruiz S; Callejo M; Pandolfi R; Villa-Valverde P; Rodríguez I; Cogolludo A; Ruiz-Cabello J; Perez-Vizcaino F; Moreno L
    Front Pharmacol; 2023; 14():1228923. PubMed ID: 37377931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study.
    García Aguilar H; Gorenflo M; Ivy DD; Moledina S; Castaldi B; Ishida H; Cześniewicz P; Kusa J; Miera O; Pattathu J; Weng KP; Ablonczy L; Apitz C; Katona M; Kurosaki K; Pulido T; Yamagishi H; Yasuda K; Cisternas G; Goth M; Lippert S; Radomskyj A; Saleh S; Willmann S; Wirsching G; Bonnet D; Beghetti M
    Pulm Circ; 2022 Jul; 12(3):e12133. PubMed ID: 36186721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern view on the place of riociguat in the treatment of pulmonary hypertension.
    Valieva ZS; Taran IN; Martynyuk TV; Chazova IY
    Ter Arkh; 2018 Apr; 90(4):55-59. PubMed ID: 30701875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.